Hopewell Therapeutics, Inc.

Hopewell Therapeutics, Inc.

Biotechnology

Woburn, Massachusetts 1,329 followers

Enabling a new generation of genomic medicines for patients with high unmet medical needs.

About us

Hopewell Therapeutics is discovering, synthesizing and developing the next generation of tissue-targeted lipid nanoparticles (ttLNPs) to bring genomic medicines to patients. We are pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. Hopewell has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry leading companies. We are developing our own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of our ttLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases and neurological disorders.

Industry
Biotechnology
Company size
11-50 employees
Headquarters
Woburn, Massachusetts
Type
Privately Held
Specialties
Genomic Medicines and mRNA Therapies

Locations

Employees at Hopewell Therapeutics, Inc.

Updates

Similar pages

Browse jobs

Funding

Hopewell Therapeutics, Inc. 4 total rounds

Last Round

Seed

US$ 25.0M

See more info on crunchbase